Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
11 Nov 2024
// BUSINESSWIRE
07 Nov 2024
// BUSINESSWIRE
31 Oct 2024
// BUSINESSWIRE
13 Sep 2024
// BUSINESSWIRE
03 Sep 2024
// BUSINESSWIRE
27 Aug 2024
// BUSINESSWIRE
Details:
Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): Self-amplifying mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kostaive
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2024
Lead Product(s) : Self-amplifying mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan Approves CSL and Arcturus Updated mRNA COVID-19 Vaccine for JN.1 Strain
Details : Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Brand Name : Kostaive
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 13, 2024
Details:
ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcturus Receives FDA Clearance For ARCT-032 Inhaled mRNA Therapeutic For Cystic Fibrosis
Details : ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Brand Name : ARCT-032
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2024
Details:
LUNAR-OTC (ARCT-810) is an intravenously administered mRNA therapy utilizing company’s LUNAR delivery platform to deliver OTC mRNA to hepatocytes for treating ornithine transcarbamylase deficiency.
Lead Product(s): ARCT-810
Therapeutic Area: Genetic Disease Brand Name: LUNAR-OTC
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2024
Lead Product(s) : ARCT-810
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcturus Provides Updates on OTC Deficiency and CF Programs
Details : LUNAR-OTC (ARCT-810) is an intravenously administered mRNA therapy utilizing company’s LUNAR delivery platform to deliver OTC mRNA to hepatocytes for treating ornithine transcarbamylase deficiency.
Brand Name : LUNAR-OTC
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 01, 2024
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
Details : ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Brand Name : ARCT-032
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 28, 2024
Details:
The collaboration with Arcturus Therapeutics, to evaluate best-in-class, self-amplifying mRNA vaccines for the treatment of patients suffering from neoplasms.
Lead Product(s): mRNA Based Therapy
Therapeutic Area: Oncology Brand Name: mRNA Based Therapy
Study Phase: Discovery PlatformProduct Type: Vaccine
Recipient: Achilles Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2024
Lead Product(s) : mRNA Based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Achilles Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Achilles and Arcturus Collaborate on Second-Generation mRNA Cancer Vaccines
Details : The collaboration with Arcturus Therapeutics, to evaluate best-in-class, self-amplifying mRNA vaccines for the treatment of patients suffering from neoplasms.
Brand Name : mRNA Based Therapy
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 22, 2024
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcturus Receives Orphan Medicinal Product Designation for ARCT-032 in Cystic Fibrosis
Details : ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Brand Name : ARCT-032
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2024
Details:
ARCT-154 is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Brand Name: LUNAR-COV19
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Lead Product(s) : ARCT-154
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154,...
Details : ARCT-154 is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Brand Name : LUNAR-COV19
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 28, 2023
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Brand Name : ARCT-032
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 27, 2023
Details:
The funding will advance ARCT-032, a novel messenger RNA (mRNA) therapeutic candidate formulated with Arcturus’ LUNAR® delivery technology for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Cystic Fibrosis Foundation
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Cystic Fibrosis Foundation
Deal Size : $25.0 million
Deal Type : Funding
Details : The funding will advance ARCT-032, a novel messenger RNA (mRNA) therapeutic candidate formulated with Arcturus’ LUNAR® delivery technology for the treatment of Cystic Fibrosis.
Brand Name : ARCT-032
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 26, 2023
Details:
ARCT-154, a next generation mRNA vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The companies (Arcturus and CSL Seqirus) anticipate an approval decision by the European Commission in 2024.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Brand Name: ARCT-154
Study Phase: Phase II/ Phase IIIProduct Type: Vaccine
Sponsor: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Lead Product(s) : ARCT-154
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : CSL
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ARCT-154, a next generation mRNA vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The companies (Arcturus and CSL Seqirus) anticipate an approval decision by the European Commission in 20...
Brand Name : ARCT-154
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 05, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?